Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - GERMAN REMEDIES' FLUDORA ORAL

German Remedies launches Fludara Oral

BY OUR PHARMA CORRESPONDENT

 

20 June, 2005: German Remedies, a part of the Zydus Group, has launched Fludara Oral (Fludarabine), a drug for treatment of chronic Lymphocytic Leukaemia. The orally administered drug is a product of Berlex Inc, a US affiliate of Schering AG Germany, according to a statement issued to The Stock Exchange, Mumbai.

"We have been introducing several new therapies that can improve the quality of life for the patients and enable better disease management. With Oncology being one of our core therapy areas, this new addition further strengths our product portfolio of critical-care therapies which includes cytostatics," JC Jani executive director of Zydus Cadila, and Head of German Remedies said.

Chronic Lymphocytic Leukaemia (CLL) is a cancer of the lymphocytes and is a progressive disease, which at present, has no cure. This occurs mostly in people over the age of 50 and is rare in people under the age of 40. Patients diagnosed with CLL need to undergo chemotherapy as a part of the treatment.

Alkylating cytotoxic chemotherapies create a toxic environment within the blood to destroy malignant cells. The conventional chemotherapy has many side effects including hair loss. Fludarabine has emerged as one of the leading drugs for treatment of CLL and is used both in standalone and combination therapy modules.

This helps control CLL by shortening the life span of leukemia cells and interferes with the making of new DNA. This preventing leukemia cells from growing. With this treatment, the remission can last for several years, thereby increasing the span of survival.

Till recently, the only way to administer this important therapy was through an IV injection, which is time consuming both for the patient and the healthcare system. However, with the advent of Fludara Oral, the hassles were been able to contain, it said.

The drug also causes fewer side effects commonly seen with the conventional chemotherapy, such as hair loss. At present, German Remedies markets Holoxan, Endoxan, Niltamide in the oncology segment.


BY OUR PHARMA CORRESPONDENT

 

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Roche, Novartis lead on novel cancer therapies

US FDA grants fast track status for GSK’s HIV drug

Stem Cell Bill could be delayed in US

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Lupin launches generic ceftriaxone in US

Hormonal contraceptives safe for long-term use: WHO

Abortion pill to carry 'black box' warning

Vaccines not linked to autism, say experts

Novartis acquires Bristol-Myers’ OTC business in US

Guidant alerts on flaw in pacemakers

Awareness on Medicare drug benefit scheme low in US

NIH review finds govt scientists having ties with pharma firms

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Legionnaire's disease outbreak in US hospital in New Rochelle 

Genepharm in pact with 3 Australian distributors 

UK has new generics reimbursement scheme 

Teva gets US FDA nod for mirtazapine anti-depressant 

US patent office rejects Pfizer’s Lipitor claims 

Aethlon Medical to start trials on HIV device in India 

Panel to decide fate of Advair, Serevent and Foradil asthma drugs 

Prohibitive costs mar cancer therapy 

FDA directs Palladone withdrawal

Blindness alert on impotence drugs  

Novartis files for breast cancer drug in US, Europe  

Merck readies for $10 billion Vioxx battle  

Speak up on menopause, campaign urges US women 

Direct-To-Consumer ads mislead patients: US Senator  

EU to decide on sops for developing kids drugs  

Zidovudine by Ranbaxy gets US FDA tentative nod

Parkinson's Disease therapy triggers gambling in some patients

Parkinson's Disease symptoms may be relieved by Azilect

Are obesity and diabetes just accelerated aging?

Reducing lung infection and inflammation due to Cystic Fibrosis

Viruses may help cure cancer by killing cancer cells

New product relieves tooth pain resulting from dental sensitivity 

Cervical Cancer detector may improve on Pap Smears

Dietary supplement capsule by Liqing banned in US

Cold Stone Creamery cake batter ice-creams recalled

Guidant defibrillator recall: US FDA makes three classifications

AIDS drug stavudine by Aurobindo Pharma gets tentative US FDA approval for PEPFAR

Gates Foundation donates for a good cause

Paxil CR resupply in US pharmacies announced by GlaxoSmithKline

Viagra users not at risk of blindness: Pfizer

Stem cell research gets boost from Li Ka-shing

BiDil heart failure drug for black patients approved

Restless leg syndrome could be messing up your sleep

Glaxo Smithkline in pact with IAVI to develop AIDS drug

Pfizer acquires Vicuron Pharma for $1.9 billion

German Remedies launches Fludara Oral

Ranbaxy acquires generic product portfolio from Efarmes

Sandoz files seven ANDAs of drugs going off-patent

Elder Pharma plans unit, brand acquisition

Novasite Pharma buys PsyCheNomicS

Chemokine gets US patent for novel cancer drug

Roche gets USFDA approval for oral Xeloda

Nectar Lifesciences plans Rs 90 crore IPO 

Glaxo inks co-promotion pact with Eisai for Paritec

Early Intervention required to Prevent Diabetes

AIDS drug ahoy!

Novartis launches AMD patient counselling programme

Nanobac Life Sciences, UCSF to study kidney stones 

Surface Logix commences phase I trial for PDE-5 inhibitor

Temasek sets up $112 million pharma JV

Contraceptive from Neem, courtesy DRDO  

US FDA to source anti-HIV drugs from Indian firms  

Chemists boycott Glaxo, Novartis products  

Maharashtra phases out nerve tissue-based rabies vaccine  

Last long, really long - new sex drug soon  

Johnson and Johnson demonstrates coronary stent safety

Novartis has better breast cancer treatment

Pfizer's investigational drug reduces tumor growth

New labeling for beta-blocker Coreg 

Glaxo applies for FDA approval for Flaurix

Investigational drug for Acute Bipolar Mania And Schizophrenia

Preclinical Data Support Link Between IL-9 and Airway Hyperresponsiveness Associated With Asthma

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us